Change in Number of Shares and Votes in Moberg Pharma

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Moberg Pharma (STO:MOB) The number of shares and votes in Moberg Pharma AB (publ) has increased by 215,985 to 14,217,522 during December 2015. Therefore, there are in total 14,217,522 shares and votes in the company as of July 31, 2015. The reason

Tele2 AB: Change in the Number of Shares in Tele2

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Tele2 AB (STO:TEL2B) (STO:TEL2A) (OSE:TLE201) Tele2 AB, (“Tele2”), (NASDAQ OMX Stockholm: TEL2 A and TEL2 B), today announced that Tele2’s total number of shares has increased with 2,300,000 shares. The change refers to an issue of 2,300,000 new class C shares in December

Board Change in Opus Group

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Opus Group (STO:OPUS) Göran Nordlund, chairman of the board of Opus Group, has informed the nomination committee that he will not stand for re-election at the next AGM. Göran has been involved in the board of Opus Group for 14 years and

SCA: Conversion of Shares

STOCKHOLM, Sweden–(BUSINESS WIRE)–Regulatory News: SCA (Svenska Cellulosa AB) (STO:SCAA) (STO:SCAB) According to SCA’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such

Mycronic AB: Mycronic Receives Order for a Prexision-8 Mask Writer

TÄBY, Sweden–(BUSINESS WIRE)–Regulatory News: Mycronic (STO:MYCR) Mycronic AB (publ), has received an order for a mask writer from the Prexision series for display applications from a customer in Asia. The system is scheduled to be delivered during the fourth quarter of 2016. Mycronic offers mask

Camurus AB: Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-Acting Treatment for Opioid Dependence

PRINCETON, N.J. & LUND, Sweden–(BUSINESS WIRE)–Regulatory News: Braeburn Pharmaceuticals and Camurus  (STO:CAMX) announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration. This randomized,

MEDA: Divestment of Manufacturing Unit Euromed in Spain Completed

GÖTEBORG, Sweden–(BUSINESS WIRE)–Regulatory News: Meda AB (STO:MEDAA) (Pink Sheets:MDABY) On December 1st, 2015, Meda announced the divestment of the manufacturing unit Euromed in Spain. The divestment has now been completed. The total consideration is EUR 82 million in upfront cash for the shares of Euromed.